Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2023 | 1 |
2024 | 1 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro.
Front Immunol. 2023 Oct 2;14:1250258. doi: 10.3389/fimmu.2023.1250258. eCollection 2023.
Front Immunol. 2023.
PMID: 37876933
Free PMC article.
Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction.
Marius W, Leticia OF, Friedrich KN, Stephan M, Louisa H, Tabea S, Elisa S, Pauline W, Yi D, Qi M, Barbara S, Carsten B, Walter F, Jasmin W, Franziska B.
Marius W, et al. Among authors: louisa h.
Oncoimmunology. 2024 May 9;13(1):2346359. doi: 10.1080/2162402X.2024.2346359. eCollection 2024.
Oncoimmunology. 2024.
PMID: 38737794
Free PMC article.
Item in Clipboard
Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer.
Weimer P, Wellbrock J, Sturmheit T, Oliveira-Ferrer L, Ding Y, Menzel S, Witt M, Hell L, Schmalfeldt B, Bokemeyer C, Fiedler W, Brauneck F.
Weimer P, et al. Among authors: hell l.
Cells. 2022 Mar 11;11(6):964. doi: 10.3390/cells11060964.
Cells. 2022.
PMID: 35326415
Free PMC article.
Item in Clipboard
Cite
Cite